The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Yoshii N, Suzuki T, Nagashima M, Kon A, Kakihata K, Gemma A

Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.

Anti-cancer drugs. 2011;22(6):563-8

Michielin O, Udry E, Périard D, Matzinger O, Lobrinus JA, Stupp R

Irinotecan-induced interstitial pneumonia.

The Lancet. Oncology. 2004;5(5):322-4

Madarnas Y, Webster P, Shorter AM, Bjarnason GA

Irinotecan-associated pulmonary toxicity.

Anti-cancer drugs. 2000;11(9):709-13

Yamada M, Kudoh S, Hirata K, Nakajima T, Yoshikawa J

Risk factors of pneumonitis following chemoradiotherapy for lung cancer.

European journal of cancer (Oxford, England : 1990). 1998;34(1):71-5